Cardiovascular · Phase 2-3 · pulled 2026-11-06

Hypertension: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of hypertension (last 12 years), plus 280 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Hypertension: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Seoul National University Hospital Seoul, South Korea · 33 spellings merged	30 24 completed, 6 terminated	NCT07073820 NCT06137742 NCT06030193 6 trials with titles NCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 terminated 2026-10-09 Stop reason on the record: “The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension completed 2026-07-31 NCT06030193 Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) completed 2026-03-23 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) completed 2025-11-20	2026-10-09	14 NCT07919405 NCT04175600 NCT04273945 NCT05179876	95
2	Mayo Clinic Jacksonville Jacksonville, United States · 22 spellings merged	24 16 completed, 8 terminated	NCT04816604 NCT04945460 NCT07082816 6 trials with titles NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT07082816 Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction completed 2026-04-06 NCT06864104 A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) completed 2026-03-17 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis terminated 2025-04-10 Stop reason on the record: “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.”	2026-09-09	11 NCT05968430 NCT07064473 NCT06857955 NCT06274801	78
3	Thoraxklinik-Heidelberg gGmbH Heidelberg, Germany · 18 spellings merged	20 10 completed, 10 terminated	NCT07073820 NCT04816604 NCT06137742 6 trials with titles NCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 terminated 2026-10-09 Stop reason on the record: “The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension completed 2026-07-31 NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22	2026-10-09	7 NCT04175600 NCT05587712 NCT06274801 NCT07218029	69
4	Washington University School of Medicine St Louis, United States · 14 spellings merged	20 11 completed, 9 terminated	NCT04945460 NCT03626688 NCT05934526 6 trials with titles NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18 NCT05769608 A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen completed 2025-01-15	2026-04-09	5 NCT04273945 NCT07064473 NCT06274801 NCT07365332	70
5	Hammersmith Hospital London, United Kingdom · 12 spellings merged	18 9 completed, 9 terminated	NCT07073820 NCT04816604 NCT06137742 6 trials with titles NCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 terminated 2026-10-09 Stop reason on the record: “The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension completed 2026-07-31 NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22	2026-10-09	7 NCT07318597 NCT06274801 NCT07218029 NCT07365332	70
6	Tufts Medical Center Boston, United States · 8 spellings merged	18 10 completed, 8 terminated	NCT04816604 NCT04945460 NCT03626688 6 trials with titles NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT06150924 Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria completed 2025-04-23 NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis terminated 2025-04-10 Stop reason on the record: “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.”	2026-09-09	5 NCT07318597 NCT07218029 NCT07365332 NCT06649110	73
7	Duke University Medical Center Durham, United States · 10 spellings merged	18 10 completed, 8 terminated	NCT05140525 NCT04945460 NCT03626688 6 trials with titles NCT05140525 Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH terminated 2026-05-01 Stop reason on the record: “Sponsor Requested” NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18 NCT05769608 A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen completed 2025-01-15	2026-05-01	11 NCT04273945 NCT07218029 NCT07746271 NCT07365332	73
8	Brigham and Women's Hospital Boston, United States · 15 spellings merged	18 11 completed, 7 terminated	NCT04945460 NCT04039464 NCT03626688 6 trials with titles NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT04039464 Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension completed 2025-12-31 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18 NCT06153693 Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension completed 2025-01-24	2026-04-09	11 NCT07923526 NCT07923591 NCT05968430 NCT07770685	74
9	University of Colorado Anschutz Medical Campus Aurora, United States · 18 spellings merged	18 9 completed, 9 terminated	NCT04945460 NCT04039464 NCT03626688 6 trials with titles NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT04039464 Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension completed 2025-12-31 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) completed 2025-11-20 NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis terminated 2025-04-10 Stop reason on the record: “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.” NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.”	2026-04-09	12 NCT03492177 NCT04175600 NCT05587712 NCT07318597	69
10	University of Cincinnati Cincinnati, United States · 9 spellings merged	17 9 completed, 8 terminated	NCT03626688 NCT05934526 NCT06664801 6 trials with titles NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) completed 2025-11-20 NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis terminated 2025-04-10 Stop reason on the record: “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.” NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18	2025-12-31	6 NCT07318597 NCT06274801 NCT07218029 NCT07365332	70
11	Mount Sinai Hospital New York, United States · 20 spellings merged	16 7 completed, 9 terminated	NCT07073820 NCT04816604 NCT06137742 6 trials with titles NCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 terminated 2026-10-09 Stop reason on the record: “The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension completed 2026-07-31 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis terminated 2025-04-10 Stop reason on the record: “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.” NCT04070573 Low Doses of Aspirin in the Prevention of Preeclampsia completed 2025-01-23	2026-10-09	4 NCT04273945 NCT07064473 NCT06616974 NCT04691154	68
12	University of Michigan Ann Arbor, United States · 4 spellings merged	16 10 completed, 6 terminated	NCT04945460 NCT05934526 NCT04365868 6 trials with titles NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis terminated 2025-04-10 Stop reason on the record: “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.” NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT05794555 LiveSMART Trial to Prevent Falls in Patients With Cirrhosis completed 2025-03-07 NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18	2026-04-09	4 NCT04273945 NCT06274801 NCT07175038 NCT04967989	75
13	Hospital Universitario 12 de Octubre Madrid, Spain · 8 spellings merged	15 8 completed, 7 terminated	NCT07073820 NCT04816604 NCT06137742 6 trials with titles NCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 terminated 2026-10-09 Stop reason on the record: “The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension completed 2026-07-31 NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22	2026-10-09	6 NCT07318597 NCT06274801 NCT07175038 NCT07218029	72
14	University of Kansas Medical Center Kansas City, United States · 9 spellings merged	15 9 completed, 6 terminated	NCT04816604 NCT04945460 NCT05934526 6 trials with titles NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) completed 2025-11-20 NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18	2026-09-09	8 NCT06274801 NCT07175038 NCT07218029 NCT07365332	72
15	Hosp Clinic de Barcelona Barcelona, Spain · 18 spellings merged	15 8 completed, 7 terminated	NCT04945460 NCT05934526 NCT06664801 6 trials with titles NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) completed 2025-11-20 NCT03904693 Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) completed 2024-09-27 NCT05036135 A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) terminated 2024-08-09 Stop reason on the record: “The IMPAHCT study demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.” NCT04968184 Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD) terminated 2024-07-10 Stop reason on the record: “Interim futility analysis showed primary endpoint not achieved”	2026-04-09	12 NCT07919405 NCT07098975 NCT07473700 NCT07318597	68
16	Vanderbilt University Medical Center Nashville, United States · 6 spellings merged	14 8 completed, 6 terminated	NCT03753204 NCT04039464 NCT04811092 6 trials with titles NCT03753204 Salt-Sensitivity and Immunity Cell Activation completed 2026-09-15 NCT04039464 Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension completed 2025-12-31 NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT05769608 A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen completed 2025-01-15 NCT05036135 A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) terminated 2024-08-09 Stop reason on the record: “The IMPAHCT study demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.” NCT05557942 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) terminated 2024-08-08 Stop reason on the record: “Results from the parent study (IMPAHCT) demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.”	2026-09-15	7 NCT05968430 NCT07602166 NCT07365332 NCT04967989	74
17	Hôpital Bicêtre Le Kremlin-Bicêtre, France · 21 spellings merged	14 7 completed, 7 terminated	NCT04816604 NCT03626688 NCT05934526 6 trials with titles NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT04780932 Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension completed 2025-07-03 NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18	2026-09-09	12 NCT04273945 NCT07318597 NCT06274801 NCT07175038	71
18	Medical University of South Carolina Charleston, United States · 10 spellings merged	14 8 completed, 6 terminated	NCT06137742 NCT04945460 NCT05934526 6 trials with titles NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension completed 2026-07-31 NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis terminated 2025-04-10 Stop reason on the record: “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.” NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18	2026-07-31	7 NCT07923526 NCT07923591 NCT07285655 NCT06274801	72
19	The Ohio State University Wexner Medical Center Columbus, United States · 7 spellings merged	13 5 completed, 8 terminated	NCT04816604 NCT04945460 NCT03626688 6 trials with titles NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis terminated 2025-04-10 Stop reason on the record: “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.” NCT04266197 Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study completed 2025-01-07 NCT05036135 A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) terminated 2024-08-09 Stop reason on the record: “The IMPAHCT study demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.”	2026-09-09	4 NCT07175038 NCT07218029 NCT07746271 NCT06814145	69
20	University of Nebraska Medical Center Omaha, United States · 7 spellings merged	13 9 completed, 4 terminated	NCT04816604 NCT04945460 NCT03626688 6 trials with titles NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) terminated 2026-09-09 Stop reason on the record: “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect s” NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18 NCT04732221 A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) completed 2024-07-02	2026-09-09	6 NCT04273945 NCT07318597 NCT06274801 NCT07218029	76
21	Cleveland Clinic Cleveland, United States · 9 spellings merged	13 6 completed, 7 terminated	NCT04945460 NCT03626688 NCT05934526 6 trials with titles NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) completed 2026-04-09 NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18 NCT05769608 A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen completed 2025-01-15	2026-04-09	7 NCT05968430 NCT07511361 NCT07218029 NCT04967989	66
22	University of Pittsburgh Medical Center Pittsburgh, United States · 14 spellings merged	13 5 completed, 8 terminated	NCT03629340 NCT04365868 NCT06153693 6 trials with titles NCT03629340 Metformin for Pulmonary Hypertension HFpEF completed 2026-02-27 NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis terminated 2025-04-10 Stop reason on the record: “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.” NCT06153693 Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension completed 2025-01-24 NCT03904693 Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) completed 2024-09-27 NCT03944512 Pravastatin to Prevent Preeclampsia terminated 2024-06-20 Stop reason on the record: “participants are no longer being examined or receiving intervention” NCT04271475 A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension terminated 2023-12-21 Stop reason on the record: “The Sponsor decided to stop the study for futility based on a recommendation by the IDMC following a pre-planned interim analysis”	2026-02-27	9 NCT07923526 NCT07923591 NCT05968430 NCT07064473	69
23	Royal Free Hospital London, United Kingdom · 13 spellings merged	13 7 completed, 6 terminated	NCT03626688 NCT05934526 NCT06664801 6 trials with titles NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) completed 2025-11-20 NCT05339087 Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH terminated 2025-07-31 Stop reason on the record: “Strategic re-prioritization by the IMP supplier. Decision not safety-related.” NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) terminated 2025-04-03 Stop reason on the record: “Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.” NCT04271475 A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension terminated 2023-12-21 Stop reason on the record: “The Sponsor decided to stop the study for futility based on a recommendation by the IDMC following a pre-planned interim analysis”	2025-12-31	7 NCT04273945 NCT07318597 NCT07285655 NCT06274801	71
24	University of Pennsylvania Philadelphia, United States · 7 spellings merged	13 8 completed, 5 terminated	NCT03626688 NCT05934526 NCT05794555 6 trials with titles NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients completed 2025-12-31 NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) completed 2025-12-22 NCT05794555 LiveSMART Trial to Prevent Falls in Patients With Cirrhosis completed 2025-03-07 NCT05769608 A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen completed 2025-01-15 NCT05036135 A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) terminated 2024-08-09 Stop reason on the record: “The IMPAHCT study demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.” NCT03944512 Pravastatin to Prevent Preeclampsia terminated 2024-06-20 Stop reason on the record: “participants are no longer being examined or receiving intervention”	2025-12-31	10 NCT05968430 NCT04273945 NCT06274801 NCT05470205	76
25	University of California San Francisco San Francisco, United States · 16 spellings merged	12 6 completed, 6 terminated	NCT07073820 NCT06137742 NCT03629340 6 trials with titles NCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 terminated 2026-10-09 Stop reason on the record: “The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension completed 2026-07-31 NCT03629340 Metformin for Pulmonary Hypertension HFpEF completed 2026-02-27 NCT05370599 Hypertension in Young Adults Trial terminated 2026-01-07 Stop reason on the record: “Funding limitations.” NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) completed 2025-02-18 NCT04266197 Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study completed 2025-01-07	2026-10-09	13 NCT07923526 NCT07923591 NCT04175600 NCT05587712	71

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Hypertension: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	InHo Chae Seoul National University Bundang Hospital	2	NCT06291207 NCT05931224	No paper matched at High or Medium confidence
2	Elliott Tapper University of Michigan	2	NCT05794555 NCT05061992	No paper matched at High or Medium confidence
3	Jinho Shin Hanyang University Seoul Hospital	2	NCT06121518 NCT04927299	PMID 42847102 Clinical hypertension, 2026 · High match PMID 42707347 Clinical hypertension, 2026 · High match PMID 42618626 Hypertension research : official journal of the Japanese Society of Hypertension, 2026 · High match
4	Craig Anderson The George Institute for Global Health, China	2	NCT03790800 NCT03785067	PMID 42921718 International journal of stroke : official journal of the International Stroke Society, 2026 · High match PMID 42154123 Digestive diseases and sciences, 2026 · Medium match
5	Cinthia L Patiño Bernal CICMEX Centro de Investigación Clínica de México S. de R.L. de C.V.	2	NCT04927299 NCT04218552	No paper matched at High or Medium confidence
6	Anthony Rodgers The George Institute	2	NCT04518293 NCT04518306	PMID 42881539 Expert review of clinical pharmacology, 2026 · High match PMID 42864128 BMJ open, 2026 · High match PMID 42837286 European stroke journal, 2026 · High match
7	Georges GB BAKRIS AHA Comprehensive Hypertension Center University of Chicago Medical Center	2	NCT04857840 NCT04277884	No paper matched at High or Medium confidence
8	Annet Kirabo Vanderbilt University Medical Center	1	NCT03753204	PMID 42802577 Clinical and experimental hypertension (New York, N.Y. : 1993), 2026 · High match PMID 42605627 Circulation research, 2026 · High match PMID 42461991 Circulation research, 2026 · High match
9	Jiang He Tulane University	1	NCT05405920	No paper matched at High or Medium confidence
10	Marshall Tulloch-Reid The University of The West Indies	1	NCT05405920	No paper matched at High or Medium confidence

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.